{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:10:19Z","timestamp":1784909419223,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178230","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:04:58Z","timestamp":1760000698000},"page":"178230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dapagliflozin monotherapy and combination therapy with telmisartan ameliorate pregabalin-induced heart failure in rats"],"prefix":"10.1016","volume":"1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-8122","authenticated-orcid":false,"given":"Zeinab M.","family":"Awwad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimaa A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaimaa M. Kh.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178230_bib1","first-page":"223","article-title":"Effects of therapeutic doses of Pregabalin on QTc interval in conscious rabbits","volume":"12","author":"Alp","year":"2008","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2025.178230_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/1440-1681.12360","article-title":"Comparison of the cardioprotective and renoprotective effects of the L\/N\u2010type calcium channel blocker, cilnidipine, in adriamycin\u2010treated spontaneously\u2010hypertensive rats","volume":"42","author":"Aritomi","year":"2015","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejphar.2025.178230_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2019.152310","article-title":"Telmisartan and captopril ameliorate pregabalin-induced heart failure in rats","volume":"428","author":"Awwad","year":"2019","journal-title":"Toxicology"},{"key":"10.1016\/j.ejphar.2025.178230_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12012-019-09553-6","article-title":"Assessment of pregabalin-induced cardiotoxicity in rats: mechanistic role of angiotensin 1\u20137","volume":"20","author":"Awwad","year":"2020","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178230_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11010-015-2449-4","article-title":"Intracellular angiotensin (1\u20137) increases the inward calcium current in cardiomyocytes. On the role of PKA activation","volume":"407","author":"De Mello","year":"2015","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2025.178230_bib6","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3390\/ph3072111","article-title":"Protein kinases as drug development targets for heart disease therapy","volume":"3","author":"Dhalla","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2025.178230_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinbiochem.2014.11.002","article-title":"Evidence based application of BNP\/NT-proBNP testing in heart failure","volume":"48","author":"Don-Wauchope","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejphar.2025.178230_bib8","first-page":"80","article-title":"Possible heart failure associated with pregabalin use: case report","volume":"23","author":"Erdo\u011fan","year":"2011","journal-title":"Agri"},{"key":"10.1016\/j.ejphar.2025.178230_bib9","doi-asserted-by":"crossref","first-page":"493129","DOI":"10.1155\/2012\/493129","article-title":"Angiotensin-(1-7)-mediated signaling in cardiomyocytes","volume":"2012","author":"Gomes","year":"2012","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.ejphar.2025.178230_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2025.178230_bib11","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178230_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.992327","article-title":"Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial","volume":"9","author":"Karalliedde","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2025.178230_bib13","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1097\/HJH.0b013e32833d01dd","article-title":"A new-generation N\/L-type calcium channel blocker leads to less activation of the renin\u2013angiotensin system compared with conventional L type calcium channel blocker","volume":"28","author":"Konoshita","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2025.178230_bib14","doi-asserted-by":"crossref","first-page":"H1500","DOI":"10.1152\/ajpheart.2000.278.5.H1500","article-title":"Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure","volume":"278","author":"Langenickel","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2025.178230_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijcard.2021.05.029","article-title":"Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19","volume":"336","author":"Li","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178230_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.phrs.2017.06.005","article-title":"The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases","volume":"125","author":"Li","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2025.178230_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/14791641231197106","article-title":"Dapagliflozin attenuates cardiac remodeling and dysfunction in rats with \u03b2-adrenergic receptor overactivation through restoring calcium handling and suppressing cardiomyocyte apoptosis","volume":"20","author":"Liu","year":"2023","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.ejphar.2025.178230_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-80829-w","article-title":"Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction","volume":"14","author":"Ma","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178230_bib19","first-page":"502","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia","volume":"35","author":"Mease","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejphar.2025.178230_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.019","article-title":"Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease","volume":"164","author":"Michel","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178230_bib21","article-title":"Dapagliflozin improves heart failure symptoms and physical limitations across the full range of ejection fraction: pooled patient-level analysis from DEFINE-HF and PRESERVED-HF trials","volume":"16","author":"Nassif","year":"2023","journal-title":"Circu. Heart Fail."},{"key":"10.1016\/j.ejphar.2025.178230_bib22","doi-asserted-by":"crossref","first-page":"594361","DOI":"10.1155\/2012\/594361","article-title":"Protective role of the ACE2\/Ang\u2010(1\u20139) axis in cardiovascular remodeling","volume":"2012","author":"Ocaranza","year":"2012","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.ejphar.2025.178230_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00424-012-1146-3","article-title":"AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function","volume":"465","author":"Padia","year":"2013","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.ejphar.2025.178230_bib24","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2459\/JCM.0b013e3282fb7629","article-title":"Possible heart failure exacerbation associated with pregabalin: case discussion and literature review","volume":"9","author":"Robert Lee Page","year":"2008","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2025.178230_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1476-7120-10-40","article-title":"Early detection of doxorubicin myocardial injury by ultrasonic tissue characterization in an experimental animal model","volume":"10","author":"Romano","year":"2012","journal-title":"Cardiovasc. Ultrasound"},{"key":"10.1016\/j.ejphar.2025.178230_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2004.01.001","article-title":"Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial","volume":"109","author":"Sabatowski","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2025.178230_bib27","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.7150\/ijbs.7.1077","article-title":"Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2\/angiotensin 1-7\/mas receptor axis","volume":"7","author":"Sukumaran","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejphar.2025.178230_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1253\/circj.CJ-08-1071","article-title":"Peroxisome proliferator-activated receptor \u03b3 and cardiovascular diseases","volume":"73","author":"Takano","year":"2009","journal-title":"Circ. J."},{"key":"10.1016\/j.ejphar.2025.178230_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.15420\/ecr.2018.34.2","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors in heart failure: potential mechanisms of action, adverse effects and future developments","volume":"14","author":"Tamargo","year":"2019","journal-title":"Eur. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178230_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1181473","article-title":"Optimal treatment for post-MI heart failure in rats: dapagliflozin first, adding sacubitril-valsartan 2 weeks later","volume":"10","author":"Tao","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2025.178230_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel \u03b12\u2013\u03b4 (alpha2\u2013delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejphar.2025.178230_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106659","article-title":"Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome","volume":"188","author":"Urbanek","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2025.178230_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1570159X1201140117162802","article-title":"Pregabalin in neuropathic pain: evidences and possible mechanisms","volume":"12","author":"Verma","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2025.178230_bib34","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejphar.2025.178230_bib35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cbi.2015.12.010","article-title":"Doxorubicin toxicity changes myocardial energy metabolism in rats","volume":"244","author":"Wu","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejphar.2025.178230_bib36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:33:10Z","timestamp":1779323590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925009847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"alternative-id":["S0014299925009847"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178230","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin monotherapy and combination therapy with telmisartan ameliorate pregabalin-induced heart failure in rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178230"}}